HCM
VRTX icon

HMS Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

HMS Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,900
Closed -$517K – 167
2020
Q3 		$517K Hold
1,900
– – 0.2% 93
2020
Q2 		$552K Buy
+1,900
New +$515K 0.24% 90

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HMS Capital Management's VRTX Position: Q1 2026 in Review

HMS Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 497 shares worth $222K. The position accounts for 0.09% of the portfolio, ranked #110.

HMS Capital Management first reported a position in VRTX in Q2 2018 and has held it in 27 quarters since. The position peaked at $1.71M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • HMS Capital Management held 497 shares of Vertex Pharmaceuticals worth $222K as of Q1 2026.
  • HMS Capital Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.09% of HMS Capital Management's portfolio in Q1 2026, its #110 holding.
  • HMS Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 27 quarters since.
  • HMS Capital Management's Vertex Pharmaceuticals position peaked at $1.71M in Q2 2020.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on HMS Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.